One injection every six months instead of daily pills
No Brasil, onde doenças cardiovasculares figuram entre as principais causas de morte, a Anvisa aprovou em junho de 2023 o Sybrava, um medicamento injetável da Novartis que silencia geneticamente a produção da proteína PCSK9 para reduzir o colesterol LDL. A novidade não é apenas farmacológica: com doses a cada seis meses, o tratamento desafia a lógica da adesão cotidiana que tantos pacientes não conseguem manter. É um lembrete de que a medicina avança não só na eficácia, mas também na tentativa de se adaptar à fragilidade humana diante da rotina.
- O colesterol LDL elevado continua sendo um dos maiores fatores de risco para infartos e AVCs — as duas principais causas de morte no Brasil e no mundo.
- Muitos pacientes falham em manter regimes diários de medicamentos, tornando o controle do colesterol um desafio crônico de adesão, não apenas de ciência.
- O Sybrava age bloqueando a produção da proteína PCSK9, impedindo o acúmulo de LDL nas artérias com apenas duas injeções no primeiro ano e uma a cada seis meses depois.
- A Anvisa aprovou o medicamento em 19 de junho, abrindo caminho para que adultos com colesterol resistente a outras terapias tenham uma nova alternativa no mercado brasileiro.
- O tratamento não substitui estatinas nem mudanças alimentares — é uma camada adicional para casos que exigem controle mais agressivo, e está restrito a maiores de 18 anos.
A Anvisa aprovou em 19 de junho o Sybrava, medicamento injetável desenvolvido pela farmacêutica suíça Novartis para reduzir o colesterol LDL — aquele que se deposita nas paredes das artérias e aumenta o risco de infarto e AVC. O princípio ativo é o inclisiran, que age silenciando o sinal genético responsável pela produção da proteína PCSK9, interrompendo assim a geração de lipoproteínas de baixa densidade no organismo.
A forma de administração distingue o Sybrava de boa parte dos tratamentos convencionais: uma injeção subcutânea no abdômen, aplicada por profissional de saúde, seguida de uma segunda dose após três meses e, a partir daí, uma aplicação a cada seis meses. Esse intervalo longo é visto como uma vantagem concreta para pacientes que têm dificuldade em manter regimes diários ou semanais.
A Novartis deixa claro, porém, que o medicamento não é uma solução isolada. Mudanças na dieta são exigidas antes e durante o tratamento, e o uso concomitante de estatinas pode ser recomendado pelo médico. O Sybrava é aprovado apenas para adultos e se destina especialmente a quem não consegue controlar o colesterol adequadamente com as terapias já disponíveis. Se a conveniência das doses semestrais se traduzirá em melhores resultados clínicos no mercado brasileiro, o tempo dirá.
Brazil's health regulator gave the green light on June 19 to Sybrava, a new injectable medication from Swiss pharmaceutical company Novartis designed to lower what doctors call bad cholesterol—the LDL that accumulates in artery walls and sets the stage for heart attacks and strokes.
The drug works by blocking production of a protein called PCSK9, which plays a role in how the body generates low-density lipoproteins. By stopping that protein, Sybrava prevents the buildup of LDL cholesterol in the bloodstream and along arterial walls. The active ingredient doing this work is inclisiran, a substance that essentially silences the genetic signal for PCSK9 production.
The medication comes as a prefilled syringe containing an injectable solution. A doctor or trained healthcare professional administers it as a subcutaneous injection into the abdomen. The treatment schedule is straightforward but requires patience: a first injection, then a second dose three months later, and from that point forward, one injection every six months. This long interval between doses—half a year—represents a significant advantage over daily or weekly cholesterol medications that many patients struggle to take consistently.
Novartis emphasizes in the medication's official labeling that Sybrava works best when paired with lifestyle changes. Patients need to adopt and maintain a cholesterol-lowering diet before starting treatment and continue it throughout. The company also recommends that doctors consider prescribing statins alongside Sybrava, meaning this new injection is not meant to replace existing cholesterol medications but to complement them for patients who need more aggressive control.
The drug is approved only for adults eighteen and older. The Ministry of Health notes that when LDL cholesterol levels remain elevated, the excess particles deposit themselves along artery walls, forming fatty plaques that narrow blood vessels. This narrowing increases the risk of blockages that can trigger heart attacks or strokes—the two leading causes of death in Brazil and worldwide.
For patients whose cholesterol remains stubbornly high despite diet and other medications, Sybrava offers a new option that requires only two injections in the first year and then one every six months thereafter. Whether this convenience translates into better patient adherence and ultimately better health outcomes remains to be seen as the drug enters the Brazilian market.
Notable Quotes
Novartis recommends that dietary changes be adopted before and during treatment, and that statins or other cholesterol medications be used alongside Sybrava— Novartis (per medication labeling)
Excess LDL can deposit in artery walls, forming fatty plaques that increase the risk of blockage, heart attack, and stroke— Brazil's Ministry of Health
The Hearth Conversation Another angle on the story
Why does a six-month injection matter more than another daily pill?
Because most people don't take daily pills consistently. Miss a few doses of a statin and your cholesterol creeps back up. With Sybrava, you get one shot every half year—it's harder to forget, and the drug stays in your system working the whole time.
So this isn't replacing statins?
No. Novartis is clear about this. They want doctors using both. Some patients' cholesterol is so resistant that diet plus statins still isn't enough. This drug blocks a different pathway in how the body makes LDL, so combining them attacks the problem from two angles.
What's the actual mechanism—how does blocking this PCSK9 protein help?
PCSK9 is like a cleanup crew that removes receptors from liver cells. Those receptors are what pull LDL out of the bloodstream. When PCSK9 is working normally, it removes too many receptors, so LDL stays circulating. Inclisiran shuts down PCSK9 production, which means more receptors stay on the liver cells, which means more LDL gets pulled out of your blood.
And the fatty plaques in arteries—can this reverse damage that's already there?
The drug prevents new buildup and slows existing plaques. Whether it actually shrinks plaques already formed is a different question, and that's why diet and other medications still matter. You're trying to stop the problem from getting worse while your body has time to heal.
Who really needs this? Everyone with high cholesterol?
No. People whose LDL stays high even with diet and statins. Maybe someone with a genetic predisposition to high cholesterol, or someone who can't tolerate statins, or someone whose numbers just won't budge. It's for the difficult cases.